Atlas Trials

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

Clinical trial NCT01203020 · COMPLETED

Trial details

NCT number
NCT01203020
Sponsor
West Virginia University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hodgkin's LymphomaNon-Hodgkin's Lymphoma
Start date
2010-10-12
Primary completion
2021-09-27
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.